Changes and significance of plasma VEGF pre-and post-transarterial chemoembolization in patients with BCLC stage B hepatocellular carcinoma
10.12025/j.issn.1008-6358.2017.20170025
- VernacularTitle:BCLCB期肝癌经动脉化疗栓塞术前后VEGF的表达变化及意义
- Author:
Wei ZHANG
1
;
Gao-Quan GONG
;
Chang-Yu LI
;
Guo-Ping LI
;
Yi CHEN
;
Cheng-Gang WANG
;
Qing-Bing WANG
;
Min-Jie YANG
;
Jie-Min CHENG
;
Xiao-Lin WANG
Author Information
1. 上海市影像医学研究所
- Keywords:
vasculaendothelial growth factor;
hepatocellulacarcinoma;
transcathetearterial chemoembolization;
clinic livecancestaging
- From:
Chinese Journal of Clinical Medicine
2017;24(2):219-223
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the changes of plasma VEGF levels and its relationship with efficacy of transarterial chemoembolization (TACE) for patients with Barcelona Clinic Liver Cancer Staging (BCLC) stage B hepatocellular carcinoma, and also discuss its possible clinical significance.Methods:Peripheral blood samples were collected at 1 d before TACE and at 1, 3, 5, 7, 14, 30 d after TACE from 17 patients with BCLC stage B HCC.The relationship between plasma VEGF level and biological or imaging characteristics pre-and post-TACE were analyzed.Results:Compared with 1 day before surgery, the VEGF level at 1 day after surgery was improved, and decreased at 3 and 5 days after surgery, but increased significantly at 14 days after surgery (P<0.05).Higher levels of plasma VEGF were observed in patients with fistula between hepatic artery and portal vein, or with tumor recurrence.Good response to TACE were observed in 10 patients, 7 patients with poor response.There were significant differences between two groups on plasma VEGF level at 14 d post-TACE(P<0.05).Conclusions:The plasma VEGF level can be regarded as index to evaluate the efficacy of TACE for patients with BCLC B stage.
